Genzyme's Synvisc-One set for US device panel review
This article was originally published in Scrip
Executive Summary
Genzyme's next-generation viscosupplementation product Synvisc-One will be reviewed by the USFDA's orthopaedic and rehabilitation devices advisory panel on December 9th. Genzyme is seeking an indication for the treatment of pain in patients with osteoarthritis of the knee who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics. The product is longer-acting version of Synvisc (hylan G-F 20), with one intra-articular injection providing six months of pain relief compared with three once-weekly injections for the original product. Genzyme filed the premarket approval application in June 2007. In November 2007 the FDA requested additional analysis and data, and the company responded in June. Genzyme expects FDA action on the application by December 23rd.
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.
Preterm Birth Prevention Studies Need To Look Beyond Makena Endpoints, Experts Say
Gestational age and a binary, neonatal composite endpoint are insufficient to assess outcomes that are important to babies and families, clinicians and researchers say, suggesting development of continuous variables or scales with weighted components and a comparison of outcomes among newborns in gestational age ‘buckets.’